A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (NCT06045806)

🧪 Interventions in This Study

• idecabtagene vicleucel (BIOLOGICAL)
• Lenalidomide (DRUG)
• Fludarabine (DRUG)
• Cyclophosphamide (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (101 Sites)

Showing the first 25 of 101 sites.

• Local Institution - 0131 — Los Angeles, California
• Local Institution - 0126 — Orange, California
• Local Institution - 0113 — Sacramento, California
• Colorado Blood Cancer Institute — Denver, Colorado
• Yale University School of Medicine — New Haven, Connecticut
• AdventHealth Orlando — Orlando, Florida
• Local Institution - 0121 — Atlanta, Georgia
• Local Institution - 0104 — Atlanta, Georgia
• Local Institution - 0151 — Boston, Massachusetts
• Ascension Providence Hospital — Southfield, Michigan
• M Health Fairview Clinics and Surgery Center — Minneapolis, Minnesota
• Washington University School of Medicine — St Louis, Missouri
• Washington University School of Medicine — St Louis, Missouri
• Columbia University Irving Medical Center — New York, New York
• Novant Health Cancer Institute - Elizabeth — Charlotte, North Carolina
• The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
• Local Institution - 0132 — Philadelphia, Pennsylvania
• Local Institution - 0124 — Austin, Texas
• Local Institution - 0109 — Houston, Texas
• University of Texas MD Anderson Cancer Center — Houston, Texas
• Local Institution - 0007 — Camperdown, New South Wales
• Local Institution - 0005 — Brisbane, Queensland
• Local Institution - 0004 — Melbourne, Victoria
• Local Institution - 0006 — Melbourne, Victoria
• Local Institution - 0008 — Melbourne, Victoria

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Multiple Myeloma

• Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
• A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
• Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
• MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
• A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
• A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey

Explore by condition: All Multiple Myeloma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.